drugset / Trial / NCT04762030
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
NaSingle-groupOpen-labelTreatment
Summary
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
Timeline
- Start
- 2021-02-08
- Primary completion
- 2023-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Catequentinib | Small molecule | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |